Literature DB >> 14612918

Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation.

Juergen-Theodor Fraenzer1, Huiqi Pan, Lauro Minimo, George M Smith, Dan Knauer, Gene Hung.   

Abstract

The loss of NF2 gene function leads to vestibular nerve schwannoma formation in humans. The NF2 gene product, Merlin/Schwannomin, has recently been found to interact with the two PDZ domains containing protein EBP50/NHE-RF, which is itself known to interact with the PDGF receptor (PDGFR) in several cell types. In this study, an up-regulation of both PDGFR and EBP50/NHE-RF, and an interaction of both proteins were found in primary human schwannoma tissue. Furthermore, using an adenoviral vector mediated gene transfer technique, changes in the phenotypic characteristics after NF2 gene restoration in a newly established NF2 gene-mutated human schwannoma cell line (HEI 193) were investigated. The overexpression of Merlin/Schwannomin in HEI 193 led to an inhibition of cell proliferation under serum-free conditions. Upon PDGF stimulation in culture, Merlin/Schwannomin appeared to inhibit the activation of the MAPK and PI3K signaling pathways, impinging on the phosphorylation of Erk 1/2 and Akt, respectively. The data also show that PDGFR is more rapidly internalized by the schwannoma cells overexpressing NF2. Therefore, this process is suggested as a model for a mechanism of Merlin/Schwannomin tumor suppressor function, which intermediates acceleration of the cell surface growth factor degradation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612918

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  39 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

2.  Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin.

Authors:  Minja Laulajainen; Taru Muranen; Tuula A Nyman; Olli Carpén; Mikaela Grönholm
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

3.  NHERF1/EBP50 in Breast Cancer: Clinical Perspectives.

Authors:  Antonia Bellizzi; Andrea Malfettone; Rosa A Cardone; Anita Mangia
Journal:  Breast Care (Basel)       Date:  2010-04-09       Impact factor: 2.860

Review 4.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

5.  Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants.

Authors:  Lorena B Benseñor; Kari Barlan; Sarah E Rice; Richard G Fehon; Vladimir I Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

6.  Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.

Authors:  Lu Zhou; Emanuela Ercolano; Sylwia Ammoun; M Caroline Schmid; Magdalena A Barczyk; Clemens Oliver Hanemann
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

7.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

8.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

10.  Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.

Authors:  Deborah N Chadee; Dazhong Xu; Gene Hung; Ali Andalibi; David J Lim; Zhijun Luo; David H Gutmann; John M Kyriakis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.